CD81 and myeloid sarcoma: Here, we used immuno-affinity capture for CD63 or CD81 and magnetic isolation to separate and enrich CD63+EVs and CD81+EVs, respectively, from each 500 μl of plasma of MS patients (n = 9) and HC (n = 5).